Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus

E-ISSN： 2212-389x|8|2|156-164

ISSN： 1574-3624

Source： Current Signal Transduction Therapy, Vol.8, Iss.2, 2013-08, pp. : 156-164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials 艾格列净治疗2型糖尿病：基于3期试验的安全性与有效性概述

JOURNAL OF DIABETES, Vol. 7, Iss. 4, 2015-07 ,pp. : 448-461

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incretin-based therapies and their future in Type 2 diabetes mellitus

By Sonnett Travis E Robinson Jennifer D Bowen Kurt A

Therapy, Vol. 8, Iss. 2, 2011-03 ,pp. : 143-152

Future Medicine

Access to resources Recommend Favorite

Type 2 diabetes mellitus and bone

JOURNAL OF INTERNAL MEDICINE, Vol. 283, Iss. 2, 2018-02 ,pp. : 140-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 10, 2015-10 ,pp. : 1071-1087

John Wiley & Sons Inc

Access to resources Recommend Favorite

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 1368-5031, Iss. 10, 2015-10 ,pp. : 1071-1087

John Wiley & Sons Inc

Access to resources Recommend Favorite